Abstract
Purpose
Treatment effect of radiofrequency ablation (RFA) is traditionally accomplished with MRI and/or CT. The aim of the study was to assess the role of FDG-PET in post RFA hepatic tumor evaluation, in comparison with MRI and CT.
Materials and methods
28 patients (33 hepatic RFA lesions) who had post RFA FDG-PET within 8 weeks of abdominopelvic MRI or CT were retrospectively reviewed. Accuracy of FDG-PET on post hepatic RFA evaluation was compared with MRI and/or CT based on clinical and imaging follow-up.
Results
Among total of 33 RFA-treated lesions, 17 had residual or recurrent tumor (positive). PET identified 16 with a sensitivity of 94.1 %. Of these 17 lesions, 12 had concurrent MRI and 8 were positive with a sensitivity of 66.7 %. Similarly, 6 out of the 17 lesions had CT and 4 were positive with a sensitivity of 66.7 %. Sixteen lesions were successfully ablated (negative). Among them FDG-PET was negative in 13 with a specificity of 81.3 %; MRI was performed in 8 and 7 were negative with a specificity of 87.5 %; CT was performed in 8 and 5 were negative with a specificity of 62.5 %. The overall accuracy of PET, MRI and CT was 87.9, 75.0, and 64.3 %, respectively. The average scan numbers for PET, MRI and CT to achieve a final accurate diagnosis were 1.121, 1.316 and 1.250, with a corresponding cost of $1455.2, $1845.8, and $933.8, respectively.
Conclusions
The study suggests that FDG-PET is superior to MRI and/or CT and is more cost-effective in post RFA hepatic tumor assessment.
Similar content being viewed by others
References
Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. J Surg. 1990;77:1241–6.
Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–46.
Harmon KE, Ryan JA Jr, Biehl TR, Lee FT. Benefits and safety of hepatic resection for colorectal metastases. Am J Surg. 1999;177:402–4.
Parikh AA, Curley SA, Fornage BD, Ellis LM. Radiofrequency ablation of hepatic metastases. Semin oncol. 2002;29:168–82.
Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery. 1989;106:740–8.
Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71.
Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 2002;20:4453–8.
Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg. 2002;235:466–86.
Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221:159–66.
Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities—part II. J Vasc Interv Radiol. 2001;12:1135–48.
Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology. 2001;220:145–9.
Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23:1358–64.
Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg. 2003;90:1240–3.
Kuehl H, Stattaus J, Hertel S, Hunold P, Kaiser G, Bockisch A, et al. Mid-term outcome of positron emission tomography/computed tomography-assisted radiofrequency ablation in primary and secondary liver tumours—a single-centre experience. Clin oncol (R Coll Radiol). 2008;20:234–40.
van Duijnhoven FH, Jansen MC, Junggeburt JM, van Hillegersberg R, Rijken AM, van Coevorden F, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol. 2006;13:651–8.
Rossi S, Buscarini E, Garbagnati F, Di Stasi M, Quaretti P, Rago M, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol. 1998;170:1015–22.
Dromain C, de Baere T, Elias D, Kuoch V, Ducreux M, Boige V, et al. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology. 2002;223:255–62.
Lim HK, Choi D, Lee WJ, Kim SH, Lee SJ, Jang HJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology. 2001;221:447–54.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.
Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer. 2000;88:2452–63.
Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med. 2003;28:192–7.
Donckier V, Van Laethem JL, Goldman S, Van Gansbeke D, Feron P, Ickx B, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol. 2003;84:215–23.
Blokhuis TJ, van der Schaaf MC, van den Tol MP, Comans EF, Manoliu RA, van der Sijp JR. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning. Scand J Gastroenterol. 2004;Suppl 241:93–7.
Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16:80–7.
Kuehl H, Antoch G, Stergar H, Veit-Haibach P, Rosenbaum-Krumme S, Vogt F, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: Initial results. Eur J Radiol. 2008;67:362–71.
Antoch G, Vogt FM, Veit P, Freudenberg LS, Blechschmid N, Dirsch O, et al. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med. 2005;46:520–5.
Vogt FM, Antoch G, Veit P, Freudenberg LS, Blechschmid N, Diersch O, et al. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT. J Nucl Med. 2007;48:1836–44.
Sironi S, Livraghi T, Meloni F, De Cobelli F, Ferrero C, Del Maschio A. Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. AJR Am J Roentgenol. 1999;173:1225–9.
Limanond P, Zimmerman P, Raman SS, Kadell BM, Lu DS. Interpretation of CT and MRI after radiofrequency ablation of hepatic malignancies. AJR Am J Roentgenol. 2003;181:1635–40.
Lencioni R, Cioni D, Bartolozzi C. Percutaneous radiofrequency thermal ablation of liver malignancies: techniques, indications, imaging findings, and clinical results. Abdom Imaging. 2001;26:345–60.
Ng KK, Lam CM, Poon RT, Shek TW, Yu WC, To JY, et al. Porcine liver: morphologic characteristics and cell viability at experimental radiofrequency ablation with internally cooled electrodes. Radiology. 2005;235:478–86.
Okuma T, Matsuoka T, Okamura T, Wada Y, Yamamoto A, Oyama Y, et al. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits. J Nucl Med. 2006;47:1351–8.
Tsuda M, Rikimaru H, Majima K, Yamada T, Saito H, Ishibashi T, et al. Time-related changes of radiofrequency ablation lesion in the normal rabbit liver: findings of magnetic resonance imaging and histopathology. Invest Radiol. 2003;38:525–31.
McGahan JP, Brock JM, Tesluk H, Gu WZ, Schneider P, Browning PD. Hepatic ablation with use of radio-frequency electrocautery in the animal model. J Vasc Interv Radiol. 1992;3:291–7.
Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. Radiology. 2005;237:123–31.
Paudyal B, Oriuchi N, Paudyal P, Tsushima Y, Iida Y, Higuchi T, et al. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep. 2007;18:1469–73.
Khandani AH, Calvo BF, O’Neil BH, Jorgenson J, Mauro MA. A pilot study of early 18F-FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. AJR Am J Roentgenol. 2007;189:1199–202.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, W., Zhuang, H., Cheng, G. et al. Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors. Ann Nucl Med 27, 58–64 (2013). https://doi.org/10.1007/s12149-012-0656-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-012-0656-6